Moffitt Cancer Center has partnered with Anixa Biosciences, Inc. (ANIX) to develop chimeric antigen receptor T-cell (CAR-T) technology. Dr. Jose Conejo-Garcia, the inventor of Anixa’s CAR-T technology and the Chair of the Department of Immunology at Moffitt, reports that experimental results from his laboratory indicate the potential efficacy of this technology as a treatment for ovarian cancer could be greatly improved through additional genetic engineering.
The Disease Challenge
Ovarian cancer is deadly and mortality rates have changed significantly in recent decades. Most women relapse after initial therapy. The pre-clinical data for the CAR-T therapy, initially developed at Moffitt, looks promising.
CAR-T therapy commences with the extraction and isolation of T-cells from individual cancer patients. A viral vector is then used to transform these T-cells to produce on their surface a molecule that enables the cell, once re-infused into the patient, to find cancer cells and kill them. With Anixa’s CAR-T therapy, the T-cells are transformed to express on their surface, the follicle stimulating hormone (FSH), which targets cells that are expressing foll...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).